Key Developments

On March 14, 2024, Bristol Myers Squibb Company, a pharmaceutical company, announced that it had received an approval from U.S. Food and Drug Administration for Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL)
In November 2022, AstraZeneca, a pharmaceutical company, announced an agreement to acquire Neogene Therapeutics Inc., a global clinical-stage biotechnology company pioneering the discovery, development, and manufacturing of next-generation T-cell receptor therapies (TCR-Ts), to offer cell therapy approach for targeting cancer
In June 2022, Bristol Myers Squibb Company, a biopharmaceutical company, announced a merger agreement with Turning Point Therapeutics, Inc., a clinical-stage precision oncology company with pipeline of drugs concentrating on solid tumors. As per agreement, Bristol Myers Squibb Company will acquire Turning Point Therapeutics, Inc. With this acquisition, the Bristol Myers Squibb Company can enhance its market growth in oncology and CAR-T cell therapies.
In May 2022, Novartis AG, a pharmaceutical company, announced that the U.S. Food and Drug Administration had approved Kymriah, a CAR-T cell therapy for the treatment of adult and pediatric patients with relapsed or refractory follicular lymphoma. Kymriah can be administered in the outpatient setting, thus, offering increased flexibility and potentially reducing the burden of therapy for patients.
In November 2021, Autolus Therapeutics, a U.K.-based clinical-stage biopharmaceutical company, announced that the company had entered into a strategic collaboration and financing agreement with Blackstone Life Sciences, an industry-leading private investment company. Under this agreement, funds managed by Blackstone will provide up to US$ 250 million in equity and product financing to support Autolus’ advancement of its CD19 CAR-T cell investigational therapy product candidate, obecabtagene autoleucel (obe-cel), as well as next generation product therapies of obe-cel in B-cell malignancies.